FDA NDA · NDA219007
WELTRUZA
Sponsor: TEVA NEUROSCIENCE INC
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
NDA219007
TYPE
NDA
ORIGINAL APPROVAL
2026-10-08
LATEST ACTION
2026-10-08
ROUTE
INJECTABLE
DOSAGE FORM
SUSPENSION, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
WELTRUZAPrescription
OLANZAPINE 531MG · SUSPENSION, EXTENDED RELEASE · INJECTABLE
WELTRUZAPrescription
OLANZAPINE 318MG · SUSPENSION, EXTENDED RELEASE · INJECTABLE
WELTRUZAPrescription
OLANZAPINE 425MG · SUSPENSION, EXTENDED RELEASE · INJECTABLE
Approval history
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →